Related Experiment Videos
Therapy for mycosis fungoides
Jeanette Lundin1, Anders Osterborg
1Department of Hematology and Oncology, Karolinska Hospital, SE-171 76 Stockholm, Sweden. jeanette.lundin@ks.se
Current Treatment Options in Oncology
|April 30, 2004
Summary
Treatment for mycosis fungoides (MF) aims to alleviate symptoms and prevent disease progression. Novel therapies like retinoids and immunotherapy show promise, potentially reducing reliance on traditional radiation and chemotherapy.
Area of Science:
- Dermatology
- Oncology
- Immunology
Background:
- Mycosis fungoides (MF) is a type of cutaneous T-cell lymphoma requiring treatment to manage symptoms and prevent complications.
- Current treatments include topical and systemic therapies, often used in combination, with varying efficacy based on disease stage.
Purpose of the Study:
- To review current and emerging treatment modalities for mycosis fungoides.
- To highlight the need for novel therapeutic approaches to improve patient outcomes.
Main Methods:
- Review of existing literature on mycosis fungoides treatments.
- Analysis of the efficacy of various therapeutic strategies, including psoralen and ultraviolet A (PUVA) radiation, chemotherapy, radiotherapy, and emerging agents.
Main Results:
- Psoralen and ultraviolet A radiation is effective for early-stage MF, inducing remissions.
- While local radiotherapy and total skin electron beam irradiation can control advanced disease, aggressive early therapy does not improve prognosis.
- Systemic therapies like pentostatin, gemcitabine, and liposomal doxorubicin show effectiveness, but responses are often short-lived.
- Emerging treatments such as retinoids (bexarotene) and immunotherapies (cytokines, vaccines, monoclonal antibodies) demonstrate significant therapeutic potential.
Conclusions:
- There is a critical need for developing novel treatments for mycosis fungoides.
- Biologically based therapies may offer a way to reduce the use of genotoxic treatments like chemotherapy and radiotherapy.